
Opinion|Videos|August 12, 2024
Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection
A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.
Advertisement
Video content above is prompted by the following questions:
- Outside of biomarkers, what clinical factors also lead to immune checkpoint inhibitor therapy underperformance?
- How can patient selection be optimized among those less likely to respond to immune checkpoint inhibitor therapy?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First-in-Class Optune Pax Device for Pancreatic Cancer
2
Bipartisan Break Up Big Medicine Act Targets Vertical Integration in Health Care
3
3-Year EPCORE NHL-1 Data Published Showing 53% Have Deep, Durable Remission
4
Screening Delays, Overlooked Symptoms Worsen CRC Outcomes in Younger Adults: Jordan Karlitz, MD
5

















